|
Allan Robins, Ph.D., is Novocell’s vice president and chief technical officer and oversees the company’s operations in Athens, Georgia. Dr. Robins began his career as operations manager at BresaGen Limited, an Australian biotechnology company, where he later became chief scientific officer and helped raise over $30 million. While at BresaGen Limited, he developed a proprietary expression system which continues to be used in BresaGen Limited’s production of protein pharmaceuticals. In 2000, Dr. Robins helped BresaGen Limited establish its United States subsidiary, BresaGen, Inc., to focus on its stem cell technology. Dr. Robins served as BresaGen, Inc.’s chief scientific officer until it merged with CyThera in 2004 and subsequently merged with Novocell later that year. Dr. Robins received a B.S. with honors in biochemistry and a Ph.D. in molecular biology from the University of Adelaide in Australia. He followed his studies with postdoctoral work at Cambridge University in England. | 